Ot­su­ka’s cy­tokine-tar­get­ing drug for IgAN clears Phase 3 hur­dle

Ot­su­ka Phar­ma­ceu­ti­cal’s 2018 pur­chase of Vis­ter­ra seems to be pay­ing off af­ter its an­ti-APRIL an­ti­body passed a reg­is­tra­tional test in a rare kid­ney dis­ease. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER